Received Clinical Trial Approval for a New Indication of Innovative Drug HSK44459 Tablets
December 31, 2025
Source: drugdu
63
Haisco announced on December 30 that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The notice approves the commencement of clinical trials for HSK44459 tablets for the treatment of inflammatory bowel disease (including ulcerative colitis and Crohn's disease). This drug was independently developed by the company with independent intellectual property rights. Pre-clinical studies indicate that it has a clear target, definite efficacy, and good safety, making it a promising effective treatment for inflammatory bowel disease. However, it should be noted that the research and development of innovative drugs involves long cycles, numerous stages, and high risks, and is subject to uncertainties.
https://finance.eastmoney.com/a/202512303605708953.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Betamethasone Sodium Phosphate Injection Approved January 9, 2026
- OpenAI releases two AI products in the healthcare field. January 9, 2026
- Say goodbye to lifelong medication? Hepatitis B patients may be entering an era of “functional cure”. January 9, 2026
- Xuantai Pharmaceutical’s “Isaconazole Sulfate for Injection” has been approved for marketing by the National Medical Products Administration, enriching new options for antifungal treatment January 9, 2026
- Fosun Pharma resubmits its application for listing of Furuitinib January 9, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
